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Abstract
Background: Benign prostatic hyperplasia affects older men. This systematic review determined
efficacy and adverse effects of finasteride.
Review methods: PubMed, the Cochrane Library, reference lists of reports, and reviews were
searched for randomised, double-blind trials of finasteride in benign prostatic hyperplasia.
Outcomes included symptom score, urinary flow rate, prostate volume, discontinuation, and
adverse effects. Relative risk and NNT or NNH were calculated for dichotomous data. Sensitivity
analyses assessed influences of baseline symptom severity, initial prostate volume, a dominating
trial, and previous interventions.
Results: Three trials had active controls and 19 had placebo. In placebo-controlled trials, 8820
patients received finasteride 5 mg and 5909 placebo over 3–48 months. Over 48 months finasteride
produced greater improvements in total symptom score, maximum urinary flow rate, and prostate
volume. Significantly more sexual dysfunction, impotence, ejaculation disorder and decreased libido
occurred with finasteride at 12 months; the NNH for any sexual dysfunction at 12 months was 14.
Significantly fewer men treated with finasteride experienced acute retention or had surgery at 24
or 48 months than with placebo; at 12 months the NNT was 49 (31 to 112) to avoid one acute
urinary retention and 31 (21 to 61) to avoid one surgery. Sensitivity analyses showed benefit with
finasteride 5 mg to be constant irrespective of the initial prostate volume.
Conclusions: Information from many patients in studies of high quality showed beneficial effects
of finasteride in terms of symptoms, flow rate and prostate volume. More utility would result if
patient centred outcomes were reported in dichotomous form.
Background
Benign prostatic hyperplasia (BPH) properly describes the
histological basis of a diagnosis of prostatic enlargement
leading to bladder outflow obstruction that gives rise to
symptoms of lower urinary tract obstruction [1]. Symp-
toms of benign prostatic enlargement occur commonly in
older men. In an unselected population of Scottish men
prevalence rates increased from 615 per thousand in the
fifth decade to 890 per thousand in the eighth decade [2].
With time symptoms generally get worse. Over five years
symptom scores in men with predominantly mild symp-
toms deteriorate by two points [3]. About 18% of men
with initially mild symptoms will develop symptoms that
are moderate over five years, with about three per thou-
sand becoming severe [3] though severe symptoms can
ameliorate with time. Over five years perhaps only 3% of
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men with initially mild symptoms might seek treatment
[3].
Outcomes chosen in clinical trials of treatments for be-
nign prostatic hyperplasia include not only symptom
scores, but maximum urinary flow rate, postvoid volume
and prostate volume, as well as clinical outcomes such as
acute urinary retention or progression to surgery [4–7].
Changes in these outcomes may occur even without active
treatment, with reductions (improvements) in symptoms
scores and increases (improvements) in maximum uri-
nary flow rate [8]. For this reason accurate evaluation of
potential benefit of interventions for symptomatic BPH
require controlled trials of at least two years duration [8].
For many alternative therapies such studies are lacking
[4]. Studies of alpha-blockers are generally less than two
years [5,9,6]. Studies of interventions like transurethral
microwave thermotherapy may have longer follow up of
between three and seven years, but the bulk of the infor-
mation is from nonblinded, uncontrolled studies [10],
and in surgical studies men generally have higher initial
symptom scores and lower maximum urinary flow rates
than is seen in medical interventions.
For finasteride some systematic reviews and meta-analy-
ses already exist [5,11]. A significant proportion of ran-
domised trials of finasteride have lasted one or two years,
and at least one large study continued beyond two years
[12]. Our aim in this systematic review and meta-analysis
was to examine results for the standard dose of 5 mg fin-
asteride according to duration of treatment so that men
and their professional advisers would know what to ex-
pect, and when, both with and without treatment.
Materials and methods
Searching
PubMed (to April 2001) and the Cochrane Library (Issue
2, 2001) were searched to identify full journal publica-
tions of randomised, double blind, placebo and active
controlled trials of finasteride in the treatment of benign
prostatic hyperplasia. Free text search terms used included
'finasteride', 'proscar', 'clinical trial', and 'benign prostatic
hyperplasia'. Systematic reviews of finasteride [5,11] were
examined, as was a list of systematic reviews in benign
prostatic hyperplasia (additional file 1) for possible refer-
ences and reference lists of all obtained articles were
checked to identify additional trials. Abstracts were not
sought. Merck, Sharp and Dohme Ltd, UK, were asked for
references of any published randomised trials for finas-
teride in the context of benign prostatic hyperplasia. Un-
published studies were not sought.
It was anticipated that patient information from major tri-
als may have been published more than once, in part or in
full, as information became available from longer use of
finasteride. For each trial, the study that provided the full-
est amount of information was included in the systematic
review and any duplicated information was excluded. Du-
plicate studies were checked to ensure that relevant infor-
mation for a particular outcome described in an excluded
study was not missing from the included trial. A number
of trials had an open-label extension in which men re-
ceived finasteride only; no open-label information was
analysed because the pre-hoc decision was to analyse only
information from trials that were both randomised and
double blind.
Each report which could possibly be described as a ran-
domised controlled trial was read independently by both
authors and scored using a commonly-used, three item,
1–5 score, quality scale [13]. Disagreements were dis-
cussed and consensus achieved. The maximum score of an
included study was 5 and the minimum score was 2.
Outcomes were abstracted after discussion with a panel of
two urologists and three general practitioners with an in-
terest in urology to discuss outcomes likely to be of pro-
fessional or patient interest. Information extracted from
the double blind trials included: (i) number of men on fi-
nasteride and placebo, (ii) symptom score (total, obstruc-
tive, bother), (iii) prostate volume, (iv) urinary flow rate
(maximum, mean), (v) discontinuation (total discontin-
uations, discontinuations because of lack of efficacy, dis-
continuations because of adverse effects), (vi)
information on adverse effects including episodes of acute
urinary retention and prostate surgery, (vii) prostate spe-
cific antigen (PSA), (viii) residual volume and (ix) total
voided volume. Absolute values and/or mean or median
values (with dispersion) were extracted. When provided,
this information was extracted for the following time-
points regardless of whether it was an intermediate or fi-
nal assessment: baseline and 3, 6, 12, 18, 24, 36 and 48
months of treatment. The type of symptom score used was
noted.
Analysis of data
Not all men in a trial may have had each outcome as-
sessed (e.g. prostate volume), or men may have discontin-
ued. For efficacy analyses, therefore, the number of men
for which information was available at a particular point
in time was used if this differed from the number ran-
domised; because results were rarely dichotomous, an in-
tention-to-treat analysis was impossible for any beneficial
outcome. For analysis of adverse effects and discontinua-
tions, the number of men randomised to treatment was
used to provide an intention-to-treat analysis.
When possible, patient information from different studies
was pooled. The objective was to enter any continuousBMC Urology 2002, 2 http://www.biomedcentral.com/1471-2490/2/14
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data in Review Manager (RevMan version 4.01; Update
Software, Oxford), to calculate weighted mean difference
from baseline for finasteride and for placebo, to generate
standard deviations or 95% confidence intervals, and to
determine statistical significance of differences between
treatments at various time points. Weighted mean values
(by group size) for continuous outcomes were calculated
using Excel:mac 2001 on a Macintosh G4.
When dichotomous information was available, relative
risk estimates, with 95% confidence intervals, were calcu-
lated using a fixed effects model [14]. A statistically signif-
icant difference between active treatment and placebo was
assumed when the 95% confidence intervals (CI) of the
relative risk did not include unity. Numbers-needed-to-
treat, with 95% confidence intervals, were calculated [15].
The confidence interval of the NNT includes no benefit of
one treatment over the other when the upper limit in-
cludes infinity. NNT is the reciprocal of the absolute risk
reduction or increase; for instance, if 75 out of 100 men
benefit with treatment and only 25 out of 100 benefit
with placebo, the absolute risk increase is 0.75–0.25 = 0.5,
and the NNT is 1/0.5 = 2.
Neither heterogeneity tests nor funnel plots were used
since they lack the power to reliably detect statistical het-
erogeneity or publication bias [16–18]. Instead, pre-
planned sensitivity analyses were conducted to detect pos-
sible variations in effect of study treatments in men with
differing aetiology or baseline severity of their condition.
The four sensitivity analyses were:
1. Comparison of differing severity of symptoms at base-
line – results of studies which included men with moder-
ate or severe symptoms at baseline were compared with
those which also included men with mild symptoms at
baseline.
2. Comparison of differing prostate volume at baseline –
results of studies which included men with small pros-
tates (mean less than 40 cm3) were compared with those
which included men with large (mean 40 cm3 or greater)
prostates at baseline. The reason for this is that there is
some evidence that finasteride is more effective in men
with prostate volumes greater than 40 cm3 [11].
3. Comparison of the results of other trials with those
from a dominating single, large, four year, double blind
trial (PLESS) [19].
4. Comparison of the results in men without prior inter-
ventional treatments and those who may have had a pre-
vious stent or balloon dilatation.
Analyses based on fewer than 500 men are not presented
in this report, because the results would not be robust
[20].
Results
Trials available for analysis
One hundred and one reports were identified as potential
randomised trials of finasteride in the treatment of benign
prostatic hyperplasia. Several of these were duplicate pub-
lications, with or without reference to previous publica-
tions. Eighty studies were excluded and reasons are given
in additional file 2. Twenty-two double blind randomised
trials from 21 reports were included in the systematic re-
view [19,21–40]. Nineteen trials were placebo controlled,
and three compared finasteride with another active treat-
ment. Full details of the included studies, with description
of men included, study duration, outcomes, and results
are shown in additional file 3, and all the baseline charac-
teristics of study groups in additional file 4.
Finasteride 5 mg daily was assessed in all included trials,
though some also included finasteride 1 mg or 10 mg.
One trial pooled information from 17 men with finas-
teride 1 mg and 15 men with finasteride 5 mg [37]; this in-
formation was included in the analyses described below.
In placebo controlled trials, 8820 men received finasteride
5 mg given once daily and 5909 men received placebo. In-
formation was available for men followed up for three
months in two trials (74 men), six months in nine (366),
12 months in six (6364), 18 months in one (55), 24
months in four (4286), and for 48 months in one (3082).
Three trials used an active control; 903 men received fin-
asteride 5 mg once daily, 553 permixon (serenoa repens),
and 358 alfluzosin 10 mg daily. Men were followed up for
six months in two studies (1870 men) and for 12 months
in one trial (489 men). Trials of active comparisons were
not followed up further because the comparators were all
different and numbers of men were small.
Men included in the trials had a clinical diagnosis of be-
nign prostatic hyperplasia, mostly based on symptoms
and urine flow rates. For symptoms, for instance, the
American Urological Association symptom scoring scale
uses seven questions which can be scored from 0 (no
problem) to 5 (severe problem); the scale can be from 0
to 35, split into mild (0–7 points), moderate (8–19
points) or severe (20–35 points) disease. At baseline,
symptoms were moderate to severe in 17 trials, and in two
studies men with mild symptoms were included. General
exclusions in the trials were men with the suggestion of
prostate cancer, urinary tract infection, previous prostate
surgery, haematuria, or those who required catheterisa-
tion for acute urinary retention.BMC Urology 2002, 2 http://www.biomedcentral.com/1471-2490/2/14
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A summary of the included trials, their size at randomisa-
tion, quality score, duration, intention-to-treat (by
number randomised) or per protocol analysis, and the
statistical significance at longest double-blind estimate is
given in Table 1. Size varied from 36 to 3040 randomised
men; nine trials randomised at least 500 men and four at
least 2000. The largest trials were of at least 12 months du-
ration. Most of the larger trials demonstrated a significant
superiority of finasteride 5 mg over placebo at the p < 0.01
level for symptom score, maximum urinary flow rate and
prostate volume; the notable exception was the VA Coop-
erative study for symptom scores and maximum urinary
flow rate because the inclusion criteria for this study in-
cluded men with small prostates [31].
Trial reports usually provided dispersion measures (stand-
ard deviation, interquartile ranges) at baseline for meas-
ures like symptom score, urine flow rate and prostate
volume. In almost no case did they provide standard de-
viations or 95% confidence intervals for intermediate
and/or final assessment for these outcome data. Conse-
quently statistical significance of differences between fin-
asteride and placebo could not be assessed for continuous
measures.
Table 1: Summary of results in the individual randomised, double blind, placebo controlled trials.
Author Number of 
patients
Quality score Duration 
(months)
ITT or PP Symptom 
score
Max urinary 
flow rate 
(mL/s)
Prostate 
volume (cm3)
McConnell et al, 
1998 PLESS
3040 4 48 PP ++ ++ ++
Marbergher et al, 
1998 PROWESS
2902 5 24 PP ++ ++ ++
Byrnes et al, 1995 2417 3 12 ITT + No data
Tenover et al, 
1997
2112 3 12 PP ++ No data
Andersen et al, 
1995
707 3 24 PP ++ ++ ++
Lepor et al, 1996 
VA cooperative 
study.
615 4 12 PP - - ++
Nickel et al, 1996 
PROSPECT
613 5 24 ITT ++ ++ ++
Gormley et al, 
1992 North 
American study
598 3 12 ITT ++ ++ ++
Finasteride study 
group, 1993 
International 
study
501 3 12 PP ++ + ++
Beisland et al, 
1992
182 3 6 ITT + + ++
Abrams et al, 
1999
121 3 12 PP - + ++
Kirby et al, 1992 50 4 3 PP ++ ++ -
Yu et al, 1995 50 3 6 PP + + +
Marks et al, 1997 41 4 6 PP - - ++
Tammela & Kont-
turi, 1993
36 3 6 ITT No data - ++
Studies with finasteride plus additional interventions
Lukkarinen et al, 
1999
61 3 24 PP - - ++
Isotalo et al, 2001 55 4 18 ITT - + ++
+ p < 0.05 ++ p < 0.01 – No significant difference between finasteride and placebo ITT Intention to treat analysis – all randomised patients PP Per 
protocol analysis – may have included men who discontinued treatmentBMC Urology 2002, 2 http://www.biomedcentral.com/1471-2490/2/14
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Symptom scores
Three different scoring systems were used. In placebo-con-
trolled trials, the Boyarsky scale (0–54) was used in two
studies, modified Boyarsky scale (0–36) in nine, and the
American Urological Association (AUA; 0–35, similar to
the current International Prostate Symptom Score, IPSS)
in eight; higher scores show worse symptoms in all three
scales. Symptom severity was recorded at baseline and at
various stages throughout the study, though not all stud-
ies reported this information for all time points, including
baseline. Figure 1 shows the weighted mean total symp-
tom scores at different time points with the American
Urological Association scale which was used for most
men, and the results for all scales are in additional file 5.
Total symptom scores were similar at baseline with finas-
teride (17) and placebo (16). They then fell (improved),
and by 12 months there was a greater reduction in symp-
tom score with finasteride (by 3.7 points) than with pla-
cebo (by 2.3 points), and maintained for 24 to 48
months. Scores continued to decrease with finasteride up
to 48 months, whereas they started to increase with place-
bo after 18 months.
Maximum urinary flow rate
Figure 2 shows the results for maximum urinary flow rate.
At baseline the weighted mean maximum urinary flow
rate was 11.2 mL/s with finasteride (3960 men) and 10.5
mL/s with placebo (3893 men). This increased (im-
Figure 1
Total symptom scores using the American Urological Association scale (0–35).
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proved) with time on treatment and by 24 months
weighted mean urinary flow rates were 12.5 mL/s with fi-
nasteride (2592 men) and 11.3 mL/s with placebo (2523
men).
Prostate volume
Figure 3 shows the results for prostate volume, which de-
clined by 25% over 24 months with finasteride compared
with a 4% decline with placebo. At baseline the weighted
mean prostate volume was 43.7 cm3  with finasteride
(2847 men) and 44.8 cm3 with placebo (2853 men). This
decreased (improved) with duration of finasteride treat-
ment, but generally increased (worsened) with placebo.
By 24 months prostate volume was 32.7 cm3 with finas-
teride (1705 men) and 43.0 cm3  with placebo (1724
men). Prostate volumes of about 30 cm3 or less are gener-
ally assumed to be normal in older men and not associat-
ed with prostatic hyperplasia [41].
Sensitivity analyses
Symptom severity at baseline
Information was pooled from studies that included men
with mild plus moderate symptoms at baseline, and was
compared with pooled information from studies includ-
ing only men with at least moderate symptoms at base-
line. Only two trials included men with mild symptoms,
with fewer than 500 per group. There was insufficient in-
formation to determine whether symptom severity at
baseline affected treatment efficacy in terms of prostate
volume or urinary flow rate.
Prostate volume at baseline
The sensitivity of results to prostate volume was investi-
gated in two ways. In the first, results were pooled accord-
ing to whether mean prostate volume of the finasteride-
treated group at baseline was less than 40 cm3 or 40 cm3
or greater. Prostate volume and maximum urinary flow
Figure 2
Maximum urinary flow rate over time.
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rate over time were determined for each data set (addi-
tional file 6). By 24 months finasteride achieved a similar
proportional reduction in prostate volume with larger
(79% of placebo) and smaller (75% of placebo) prostates.
There was limited data for maximum urinary flow rate in
men with smaller prostates, but there was no evidence
that the increased flow rate at 24 months was higher with
men with larger (110% of placebo) or smaller (108% of
placebo) prostates.
In the second, the effect of initial prostate volume on the
success of finasteride in increasing maximum urinary flow
rate in the individual trials was investigated graphically.
Figure 4 replicates the analysis of Boyle and colleagues
[11] using all trials with more than 100 men and with 12
or 24 month outcomes. In this analysis the difference be-
tween the change in maximum urinary flow rate between
baseline and study end with placebo is subtracted from
the change in maximum urinary flow rate between base-
line and study end with finasteride; what is plotted is the
difference between two differences. Higher baseline pros-
tate volume was associated with larger increases in maxi-
mum urinary flow rate for finasteride minus placebo.
These analyses were performed for the change in maxi-
mum urinary flow rate between baseline and study end
with finasteride (Figure 5) and the change in maximum
urinary flow rate between baseline and study end with
placebo (Figure 6). The benefit with finasteride 5 mg was
constant irrespective of the initial prostate volume (Figure
Figure 3
Prostate volume over time.
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Figure 4
Effect of initial prostate volume – Replication of the analysis by Boyle and colleagues.
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5). For placebo, men with higher prostate volumes had lit-
tle overall change in maximum urinary flow rate, while
men with lower prostate volumes had maximum urinary
flow rates that increased.
Influence of PLESS
Table 2 shows the results of analyses using the PLESS trial
[19] compared with results of other trials (excluding
PLESS). Not all men in the PLESS trial had prostate vol-
umes measured. In those in whom it was, the 24 month
analysis showed approximately a 10 cm3 reduction in
prostate volume (18% reduction from baseline of 55 cm3
with finasteride) for PLESS and other trials, compared
with a 4 cm3 (8%) increase in volume with placebo. Max-
imum urinary flow rates at 24 months rose with finas-
teride to the same extent (by about 2 mL per second) in
the PLESS trial with 1125 men and in the studies with
2991 men given finasteride.
Previous interventions
Only two trials [29,32] included men who had prior inter-
ventions like balloon dilatation, or catheterisation with a
stent implant. Together these two studies had only 59
men on finasteride and 60 on placebo. Sensible compari-
sons were not possible.
Discontinuation
Discontinuation was well reported in the trials.
Significantly fewer men discontinued with finasteride
than with placebo at 12 months or 48 months (Table 3A).
After 12 months, all cause discontinuation rates were 13%
(553/4098 men) with finasteride and 17% (299/1764)
with placebo; number-needed-to-treat to prevent one dis-
continuation was 29 (18 to 71). After 48 months, discon-
tinuation rates were 34% (524/1524 men) with
finasteride and 42% (633/1516) with placebo; NNH to
prevent one discontinuation was 13 (9.0 to 27).
There was no significant difference between groups at any
time point for discontinuation because of lack of efficacy
(Table 3B), with 24 month discontinuations because of
lack of efficacy at 4% with finasteride and 5% with place-
bo. There was no significant difference between groups at
any time point for discontinuation because of adverse ef-
fects (Table 3C), with 24 month discontinuations because
of adverse effects at 8% with finasteride and 14% with pla-
cebo.
Specific adverse effects
The most commonly reported adverse effects were impo-
tence, decreased libido and ejaculation disorder. Defini-
tions of these adverse effects were generally not provided
in the trials. Since cumulative adverse effect information
was not available after year one in some studies, analyses
were conducted for different time points up to one year
for most adverse effects. Numbers-needed-to-harm are
shown in Table 4 for analyses for which there were ade-
quate data. Serious adverse effects occurred at similar fre-
quencies with finasteride (12%; 437/3557 men) as with
placebo (13%; 150/1175 men).
Significantly more men reported any sexual dysfunction,
decreased libido, impotence, or ejaculation disorder with
finasteride than with placebo at 12 months of treatment.
Incidence rates ranged between 2–14% with finasteride
and 0.6–7% with placebo, and NNHs for particular ad-
verse events ranged between 14 and 55 (Table 4). This
means, for instance, that for every 24 men treated with 5
mg finasteride for 12 months impotence would occur in
one in whom it would not have occurred with placebo.
Avoiding AUR and surgery
Significantly fewer men suffered acute urinary retention or
surgery related to benign prostatic hyperplasia after 24
months (Table 4), though much of this information was
derived from the PLESS trial. Acute urinary retention and
surgery related to benign prostatic hypertrophy occurred
in less than 1% of men over the first 12 months of treat-
ment. By 24 months their occurrence was significantly
lower with finasteride than with placebo. The NNTs for
avoiding acute urinary retention were 49 (31 to 112) over
24 months and 26 (19 to 44) over 48 months. The NNTs
for avoiding prostate related surgery were 31 (21 to 61)
over 24 months and 18 (14 to 27) over 48 months. This
means, for instance, that for every 31 men treated with 5
mg finasteride for 24 months prostate surgery would be
avoided in one in whom it would have occurred with pla-
cebo.
It was not possible to calculate results for a combined end
point of avoiding acute urinary retention or surgery.
There was no statistically significant difference in the inci-
dence of prostate cancer with finasteride compared with
placebo. Rates were under 0.5% at 12 months, and in one
four year study [19] rates were 1–2% at 24 months and
0.5% at 48 months.
Discussion
Clinical trials set out to determine whether an interven-
tion is better than no treatment (placebo) or another
treatment. Their conduct is governed by rules of evidence,
and in the main they will need to be randomised and dou-
ble blind to minimize bias, have a valid design, measure
useful clinical outcomes over a sensible period, and be of
sufficient size to minimize the effects of random chance or
to have a reasonable expectation of seeing a difference if
one exists. How clinical trials are designed will often de-
pend on what happens without treatment. For instance,BMC Urology 2002, 2 http://www.biomedcentral.com/1471-2490/2/14
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Figure 5
Effect of initial prostate volume – finasteride.
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Figure 6
Effect of initial prostate volume – placebo.
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after surgery some patients do not get pain [42], and so tri-
als of analgesics recruit only patients who have moderate
or severe pain in the first place [43]. For men with mild or
moderate symptoms of BPH long duration placebo-con-
trolled trials are essential; while the natural history is for
symptoms to worsen with time [8], lifestyle changes or
tolerance mean that in some men improvement occurs
spontaneously [3].
Clinical practice is different because the choice is whether
to use an intervention or not, or which of several interven-
tions to use. Placebo is not an option, though watchful
waiting may be a sensible decision for many men [44].
The choice made will be a product of how much symp-
toms interfere with aspects of daily living, professional ad-
vice, and individual preference. Knowledge of the natural
history [45] will be part of the decision-making, together
with knowledge of what to expect from treatment.
This review sought to explore whether randomised trials
of finasteride 5 mg (the standard licensed dose in the UK)
could be used to provide an adequate estimate of what to
expect from treatment in terms of benefits (symptoms,
flow rates) and harm (acute retention, progression to sur-
gery, and adverse event discontinuation). The 19 trials
available comparing finasteride 5 mg with placebo all had
quality scores of 3 out of 5 or higher, indication that they
were likely to be free of major bias [46,47]. Ten trials, with
the bulk of the patients randomised, were of at least 12
month's duration and included more than 500 patients.
Almost all showed finasteride 5 mg to be significantly bet-
ter than placebo for each of three efficacy outcomes
(symptoms, maximum urinary flow rate and prostate vol-
ume), and mostly at a significance level of 1%. The evi-
dence is that finasteride is effective.
The question is, what can a man expect from treatment
with finasteride?
At baseline the individual studies recruited men with
mean symptom scores of 8 to 19 points, usually described
as moderate. Treatment with finasteride 5 mg for 12
months resulted in a 4 point decrease and for 24 months
in a 5 point decrease, so that using the American Urologi-
cal Association score mean values fell from 17 points at
baseline to 12 points. The range of scores for moderate
symptoms is 8–19 points, so on average men could expect
symptoms to reduce from just under severe to just over
mild. Mean urinary flow rates would rise from a mean
baseline value of 11.2 mL/s with finasteride 5 mg to 12.5
mL/s after 24 months of treatment; a flow rate of 12 mL/
sec is seen by some as a threshold for BPH [41]. This
would be accompanied by a reduction in prostate volume
by a mean of 8 cm3 to an average of about 33 cm3, and
though this would not be apparent to the patient it comes
close to the one threshold of normality for prostate vol-
ume [41]. Quality of life was looked at in several trials, but
Table 2: Comparison of other studies with information from PLESS
A. Prostate volume (cm3)
PLESS Other studies (without PLESS)
Finasteride Placebo Finasteride Placebo
Baseline Number 157 155 2719 2696
Value 55.0 54.0 43.1 44.2
24 months Number 130 119 2146 2140
Value 45.1 58.3 31.5 41.5
Mean change from baseline at 24 mths -9.9 4.3 -10.6 3.3
B. Maximum urinary flow rate (mL/s)
PLESS Other studies (without PLESS)
Finasteride Placebo Finasteride Placebo
Baseline Number 1125 1127 2991 2923
Value 11.0 11.0 10.5 10.3
24 months Number 786 720 1806 1803
Value 12.6 11.4 12.4 11.3
Mean change from baseline at 24 mths 1.6 0.4 1.9 1.0
Number of patients at baseline, or remained in the studies at 24 monthsBMC Urology 2002, 2 http://www.biomedcentral.com/1471-2490/2/14
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the challenge is to find an acceptable disease-related in-
strument that adds to current disease measures [48].
Out of every 100 men with moderate symptoms treated
with finasteride 5 mg over two years, 34 would discontin-
ue treatment for any reason. For six men it would be be-
cause of lack of treatment benefit, for 12 it would be
because of adverse events. Four men out of 100 would be-
come impotent, who would not have done with no treat-
ment. Additional benefits would be that out of 100 men
treated for two years two would avoid an episode of acute
urinary retention and three would avoid prostate-related
surgery.
The adverse events seen with finasteride have to be seen in
context. Firstly they appear to be reversible on stopping
treatment, and we found no evidence of rare, major and
irreversible adverse events, important for treatment taken
for the rest of a man's life. Discontinuations due to ad-
verse events were the same in finasteride and placebo-
treated men, and at 8% with finasteride after 24 months
about the same as seen in alpha-blockers in trials general-
ly of much shorter duration [49]. The sexual adverse
events have to be seen against the natural history of reduc-
ing sexual performance with age. For instance, sexual dys-
function in men is common [50] and increases with age
[51]; men aged 55 years without erectile dysfunction con-
sider intercourse frequency as being less than adequate
[52]. The men in the finasteride trials had an average age
of about 65 years.
It is clear that increasing prostate volume is the cause of
clinical benign prostatic hyperplasia [45]. Prostate vol-
ume is not usually measurable in general practice because
the required ultrasound equipment is not available. How-
ever, PSA acts as a surrogate measure for prostate volume,
and as a predictor for increased risk of acute urinary reten-
tion [53]. It should be noted, however, that finasteride de-
creases PSA values by a factor of about two, important to
remember if prostate cancer were suspected [54].
Table 3: Discontinuations in double blind, placebo controlled trials of 3–48 months duration Significantly fewer discontinuations with 
finasteride than with placebo.
A. Total number of patients who discontinued
Number of 
studies
Time point 
(months)
Discontinued with finasteride 
5 mg
Discontinued with placebo Relative risk 
(95% CI)
NNT (95% 
CI)
Number Percent Number Percent
13 N o  d a t a
5 12 553/4098 13 299/1764 17 0.8 (0.7 to 0.9) 29 (18 to 71)
4 24 467/2146 22 507/2140 24 0.9 (0.8 to 1.03) n/c
1 48 524/1524 34 633/1516 42 0.8 (0.7 to 0.9) 13 (9 to 27)
B. Discontinuations because of lack of efficacy
Number of 
studies
Time point 
(months)
Discontinued with finasteride 
5 mg
Discontinued with placebo Relative risk 
(95% CI)
NNT (95% 
CI)
Number Percent Number Percent
13 N o  d a t a
4 12 116/3788 3 46/1459 3 0.9 (0.7 to 1.4) n/c
4 24 81/2146 4 107/2140 5 0.8 (0.6 to 1.0) n/c
1 48 99/1524 6 104/1516 7 0.9 (0.7 to 1.2) n/c
C. Discontinuations because of adverse effects
Number of 
studies
Time point 
(months)
Discontinued with finasteride 
5 mg
Discontinued with placebo Relative risk 
(95% CI)
NNT (95% 
CI)
Number Percent Number Percent
13 N o  d a t a
5 12 251/4098 6 89/1764 5 1.2 (0.9 to 1.5) n/c
11 8 N o  d a t a
4 24 178/2146 8 210/2140 14 0.8 (0.7 to 1.02) n/c
1 48 176/1524 12 166/1516 11 1.0 (0.9 to 1.3) n/c
NB: Number-needed-to-treat to prevent one discontinuation with finasteride compared with placeboBMC Urology 2002, 2 http://www.biomedcentral.com/1471-2490/2/14
Page 14 of 17
(page number not for citation purposes)
The relationship between efficacy of finasteride and pros-
tate volume [55] has been important in making decisions
about treatment [11]. Based on an individual patient anal-
ysis of six trials Boyle and colleagues showed that while
men treated with finasteride 5 mg all had the same aver-
age increase in flow rate over one year, statistical signifi-
cance from placebo occurred only with prostate volumes
above 40 cm3. Improvements in symptom score tended to
be higher in men with larger prostates. Analysing mean
data from all trials with more than 100 men per treatment
group confirms this (Figures 4,5,6). With finasteride 5 mg
a mean improvement in maximum flow rate of about 1.5
mL/sec can be expected (Figure 5) irrespective of initial
prostate size (Figure 5).
Dependence of treatment efficacy on prostate size is likely
be related to mechanism of action, as no such relationship
has yet been demonstrated with the alpha-adrenergic re-
ceptor antagonist terazosin [9]. In terms of choosing who
should be treated, the largest and longest randomised trial
of finasteride suggest that men with higher symptom
scores and a baseline PSA of above 1.4 ng/mL will benefit
most [12]. This is confirmed by a combined analysis of all
men given placebo in finasteride trials [53]. Spontaneous
acute urinary retention over two or four years was low
when the initial PSA was less than 1.3 ng/mL, but oc-
curred in 2% of men with initial PSA between 1.4 and 3.2
ng/mL and was over 5% in men with a PSA above 3.3 ng/
mL. PSA alone was as effective as more complicated algo-
rithms at predicting acute retention [53].
Limitations of the review lie mainly in the way that effica-
cy trials in BPH are conducted and reported. For outcomes
like adverse events, discontinuations or events like acute
retention or prostate surgery, the number of men with the
event is reported; with the number of men randomised an
intention-to-treat analysis becomes possible, and pooling
of data using standard methods is possible. Not all trials
reported any or all of these outcomes, but they were re-
ported in most of the larger trials in a reasonably consist-
ent manner.
Efficacy outcomes were another matter. There are three
problems. First is the relevance of the outcomes them-
selves. For instance, maximum urinary flow rate is a useful
measure of urinary outlet obstruction, though multiple
Table 4: Adverse effects reported in double blind, placebo controlled trials of 3–48 months duration Significantly fewer adverse effects 
with finasteride than with placebo.
Adverse 
effect
Number of 
studies
Time point 
(months)
Harmed with finasteride 
5 mg
Harmed with placebo Relative risk 
(95% CI)
NNT 
(95% CI)
Number Percent Number Percent
Serious 
adverse effects
2 12 437/3557 12 150/1175 13 1.0 (0.8 to 1.1) n/c
Any sexual 
dysfunction
1 12 239/1736 14 38/579 7 2.1 (1.5 to 2.9) 14 (10 to 22)
Decreased 
libido
5 12 269/5688 5 86/3296 3 2.0 (1.6 to 2.5) 47 (35 to 74)
Impotence 6 12 439/5394 8 117/3551 3 2.2 (1.8 to 2.7) 24 (20 to 31)
Ejaculation 
disorder
5 12 137/5688 2 19/3296 0.6 3.6 (2.2 to 6.0) 55 (43 to 74)
Acute urinary 
retention
3 12 17/3803 0.4 9/1430 0.6 0.8 (0.4 to 1.9) n/c
1 24 24/1450 2 54/1452 4 0.5 (0.3 to 0.7) 49 (31 to 112)
1 48 42/1542 3 99/1516 7 0.4 (0.3 to 0.6) 26 (19 to 44)
BPH related 
surgery
5 12 54/4410 1 24/2035 1 1.1 (0.7 to 1.7) n/c
2 24 85/1760 5 142/1755 8 0.6 (0.5 to 0.8) 31 (21 to 61)
1 48 69/1542 4 152/1516 10 0.5 (0.3 to 0.6) 18 14 to 27)
Prostate 
cancer
2 12 9/3557 0.3 5/1175 0.4 0.6 (0.2 to 0.8) n/c
1 24 3/310 1 6/303 2 0.5 (0.1 to 1.9) n/c
1 48 76/1524 0.5 76/1516 0.5 1.0 (0.7 to 1.4) n/c
n/c Not calculable NB: For acute urinary retention, prostate surgery, and prostate cancer the NNT represents the number-needed-to-treat to pre-
vent one episode of acute urinary retention or prostate surgeryBMC Urology 2002, 2 http://www.biomedcentral.com/1471-2490/2/14
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measures are probably more useful than a single measure
[56]. A maximum flow rate of less than 15 mL/sec is gen-
erally considered suboptimal, though some now use a
flow rate of 12 mL/sec. So a useful outcome might be the
number of men at each time point who achieve a maxi-
mum urinary flow rate of 15 mL/sec (or 12 mL/sec [41],
or whatever is deemed clinically useful). Trials report only
mean flow rates, and, with some exceptions at baseline,
without any dispersion data in the form of standard devi-
ations or confidence intervals. So, despite many trials in-
volving nearly 14,000 men with BPH, it is not possible to
say what proportion can achieve any given maximum
flow rate with finasteride or placebo, and when. Reporting
of symptom scores is similar, so we cannot say what pro-
portion of men with initially moderate symptoms would
have symptoms reverting to mild with finasteride or pla-
cebo, or when.
Conclusions
Reporting problems in BPH treatments is not limited to fi-
nasteride trials, and is common with all treatments [5], in-
cluding alpha-blockers [9], as well as other remedies [4].
What would be useful would be some clear indications of
patient-centred outcomes, as has been done for migraine
[57]. Reporting these outcomes in dichotomous form
(success or failure) would greatly aid understanding of the
benefits for men, and for healthcare systems.
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